Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 4/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28140285 | 0.98 | CA2 (0.53) | CA2FAAHTSHRTP53CES1 | |
| SCHEMBL6050006 | 0.79 | CA2 (0.50) | CA2FAAHTSHRCES1CES2 | |
| SCHEMBL25247075 | 0.77 | — | — | |
| SCHEMBL5505478 | 0.75 | CA2 (0.59) | CA2FAAHTP53CES1CES2 | |
| SCHEMBL17138111 | 0.74 | CA2 (0.64) | CA2FAAHTP53CES1 | |
| SCHEMBL28140357 | 0.74 | TSHR (0.30) | TSHR | |
| SCHEMBL6049941 | 0.74 | CA2 (0.39) | CA2FAAHTSHRTP53 | |
| SCHEMBL14519882 | 0.73 | CA2 (0.63) | CA2FAAHTSHRTP53CES1 | |
| SCHEMBL1911477 | 0.73 | CA2 (0.63) | CA2FAAHTSHRTP53CES1 | |
| SCHEMBL11101496 | 0.73 | CA2 (0.63) | CA2FAAHTSHRTP53CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015081188-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-(ARYLSULFONYL)ALKYLNITRILE | OLATEC INDUSTRIES LLC (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-1807393-B1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| EP-1858852-B1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | GILLIGAN MYRA | 2008-11-13 | — | — | US | disclosed |
| EP-1858852-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-11-28 | — | — | EP | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1807393-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | Merck Sharp & Dohme Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| EP-1786768-A1 | ARYLSULPHONYLSTILBENE DERIVATIVES FOR TREATMENT OF INSOMNIA AND RELATED CONDITIONS | Merck Sharp & Dohme Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| WO-2006095205-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021806-A1 | ARYLSULPHONYLSTILBENE DERIVATIVES FOR TREATMENT OF INSOMNIA AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | CA2 4755/4885FAAH 113/4885TSHR 283/4885 |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | HTR2A, HTR2B, HTR2C | CA2 4678/4885FAAH 169/4885TSHR 236/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | CA2 4755/4885FAAH 113/4885TSHR 283/4885 |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | HTR2A, HTR2B, HTR1A | CA2 4755/4885FAAH 113/4885TSHR 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.